Biodexa Income Tax Expense from 2010 to 2024

BDRX Stock   5.62  0.69  14.00%   
Biodexa Pharmaceticals Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense is likely to outpace its year average in 2024. During the period from 2010 to 2024, Biodexa Pharmaceticals Income Tax Expense regression line of annual values had r-squared of  0.04 and arithmetic mean of  929,287. View All Fundamentals
 
Income Tax Expense  
First Reported
2013-03-31
Previous Quarter
62.5 K
Current Value
62.5 K
Quarterly Volatility
711.7 K
 
Yuan Drop
 
Covid
Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 268.9 K, Selling General Administrative of 3.9 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 4.15, Dividend Yield of 0.0 or PTB Ratio of 0.34. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.
  
Check out the analysis of Biodexa Pharmaceticals Correlation against competitors.
For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Latest Biodexa Pharmaceticals' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Biodexa Pharmaceticals over the last few years. It is Biodexa Pharmaceticals' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biodexa Pharmaceticals' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Pretty Stable
   Income Tax Expense   
       Timeline  

Biodexa Income Tax Expense Regression Statistics

Arithmetic Mean929,287
Geometric Mean894,882
Coefficient Of Variation80.95
Mean Deviation564,799
Median832,000
Standard Deviation752,236
Sample Variance565.9B
Range2.6M
R-Value(0.21)
Mean Square Error582.1B
R-Squared0.04
Significance0.45
Slope(35,600)
Total Sum of Squares7.9T

Biodexa Income Tax Expense History

2024-385.7 K
2023-406 K
2022832 K
2021646 K
20201.3 M
20191.8 M
2018M

About Biodexa Pharmaceticals Financial Statements

Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense-406 K-385.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.